FIGURE S1

Each specific chemical inhibitor inhibits the activity of PI3K/Akt, Erk1/2, Src, or Syk. (A) EBV-infected HCECs incubated for 48 h with 25 μM of the PI3K/Akt inhibitor LY294002, 20 μM of the Erk1/2 inhibitor PD98059, or 25 μM of LY294002 and 20 μM of PD98059 were harvested and subjected to Western blot analysis with the indicated antibodies. (B) EBV-infected HCECs incubated for 48 h with 200 nM of the Src inhibitor PP1 or 200 nM of the Syk inhibitor BAY-61-3606 were harvested and subjected to Western blot analysis with the indicated antibodies.